Market Overview

Jefferies Reiterates Hold Rating, $6 PT for Exelixis

Related EXEL
Morning Market Movers
Stocks Hitting 52-Week Lows

In a company update published earlier today, Jefferies & Company, Inc. reiterated its Hold rating and $6.00 price target for Exelixis, Inc. (NASDAQ: EXEL), related to the recent reveal of cabo NRE efficacy data.

Jefferies went on to say “The cabo NRE data, somewhat key for the mCRPC outlook and presented at ASCO, left much to be desired. Despite somewhat intriguing early data in renal and liver cancers for which further exploration is warranted, we remain concerned about cabo's clinical, regulatory and commercial prospects in mCRPC, where investor and EXEL's focus lies.”

Exelixis, Inc. closed yesterday at $4.77.

Latest Ratings for EXEL

DateFirmActionFromTo
Sep 2014Stifel NicolausDowngradesBuyHold
Sep 2014Cowen & CompanyDowngradesOutperformMarket Perform
Sep 2014Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Reiteration Analyst Ratings

 

Related Articles (EXEL)

Around the Web, We're Loving...

Get Benzinga's Newsletters